Clinical Facilities Sample Clauses

Clinical Facilities. PHYN hereby agrees to provide to the Practice on an exclusive full-time basis the offices and facilities more fully described in Exhibit 3.1 hereto. PHYN shall be responsible for paying (which costs shall be Clinical Facility Expenses) all rent, additional lease costs, costs of repairs, maintenance and improvements, upgrades, utilities (including, without limitation, telephones, cellular telephones, facsimile machines, pagers and other telecommunications devices to the extent used in the business of the Practice, electricity, gas, heat, air conditioning and water), normal janitorial services, refuse disposal including disposal of medical and hazardous waste, property taxes and assessments, parking, security services, medical records storage, and all other costs and expenses reasonably incurred in conducting operations in the Clinical Facility during the term of this Agreement. PHYN shall keep the Clinical Facilities in good order and repair, and shall provide or arrange for maintenance and repair reasonably promptly after any request from the Practice. PHYN shall notify the Practice prior to making any significant capital improvements or repairs, and PHYN shall not change or relocate the location of Clinical Facilities without the prior written consent of the Practice, which consent shall not be unreasonably delayed or withheld. PHYN and the Practice acknowledge that the Clinical Facility may be used by radiologists who are not Physician Employees to provide radiology professional services.
Sample 1
AutoNDA by SimpleDocs
Clinical Facilities. LOCATION ADDRESS ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- Abilene - Texas Cancer Center Abilene South 1957 Antixxxx Xxxd 79606 ------------------------------------------------------------------------------------------------------- Abilene - (N) 1100 Xxxxx 00xx Xx., Xxx. 0X, 0X 79601 ------------------------------------------------------------------------------------------------------- Alamagordo, NM 1209 0xx Xxxxxx 00000 ------------------------------------------------------------------------------------------------------- Xxxxxxxxx - (X) 801 Road to Six Flags, Ste. 105 76012 ------------------------------------------------------------------------------------------------------- Arlington - Texas Cancer Center Arlington 515 Xxxx Xxxxxxxx, Xxx. 101 76014 ------------------------------------------------------------------------------------------------------- Athens 302 Xxxxxx Xx. 75751 ------------------------------------------------------------------------------------------------------- Austin 1600 X. 00xx Xx., Xxxx. 004, 120 & 122 78731 ------------------------------------------------------------------------------------------------------- Austin 11110 Xxxxxxxx Xxxx., Xxx. 000 00000 ------------------------------------------------------------------------------------------------------- Austin - South Austin Cancer Center 4101 Xxxxx Xxxxx Xx. 78745 ------------------------------------------------------------------------------------------------------- Beaumont 690 X. 00xx Xx. 00000 2nd and 3rd Floors ------------------------------------------------------------------------------------------------------- Big Spring 1501 X. 00xx Xxxxx 00000 ------------------------------------------------------------------------------------------------------- Brownsville - South Texas Cancer Center 2150 X. Xxxxxxxxxx 00 78521 ------------------------------------------------------------------------------------------------------- Brownwood 118 Xxxxx Xxxx Xxxxx 00000 ------------------------------------------------------------------------------------------------------- Burnxx 000 Xxxxxxxx Xx. 78611 ------------------------------------------------------------------------------------------------------- Clifton 201 X. Xxx. XXXX 00000 -------------------------------------------------------------------------------------------...
Sample 1
Clinical Facilities. General Explanation Clinical facilities are, as the whole Subfaculty of Dentistry, during the period of transition. The new building is partly equipped with modern dental chairs/units because the completing of the whole investment is planned for year 2001. So, temporarily, old equipment is used at present as the supplement. The whole building is computerised, administration, treatment rooms etc. so patients shall have a file in a central registration room. Special, computerised registration system is being introduced. There is central sterilisation room. There are six main Departments/Clinics: Department and Clinic of Maxillofacial Surgery: units for surgery, surgical rooms, operation theater, beds for patients. There is equipment for treating patients under general anaesthesia and nitrous oxygen sedation. This Clinic is situated on one of the floor`s in the building of Rydygier`s Hospital and will remain as the building is new, modern and Clinic cooperates with other medical departments there. Department and Clinic of Oral Surgery: 9 units for surgery (5 old + 4 new) in 2 surgical rooms, 1 operation theater (with one unit/chair), 1 room with 4 beds for patients Department and Clinic of Prosthetics: 29 units for dental/prosthetic care (11old+ 13 new + 5 operational) Equipment: Co2 laser Technical facilities : 1 laboratory Department and Clinic of Orthodontics: 9 units for dental/orthodontic care (4 old + 5 new ) in rooms. Equipment: program for computerised evaluation of cephalometric x- ray pictures. Technical facilities: 1 laboratory Department and Clinic of Conservative Dentistry: 37 units for dental care (paedodontia, periodontics, oral mucosa diseases, cariology, endodontics) ( 28 old + 9 new) 1 unit for periodontal surgery. Equipment: radiovisiography, intraoral camera, lasers ( hard and soft lasers) Department and Clinic of Introduction for Conservative Dentistry: 13 units for dental care (9 old + 4 new) Central Outpatients Department : 2 units/chairs Total number of dental chairs/units in the Dental Institute : 97 Strengths As all the dental chairs are in the same building, and they are of multipurpose use, they might be used according to undergraduate and postgraduate teaching needs. There is also possibility of interdisciplinary consultation all the time. After completion of investment the Dental Institute will be well – designed, with modern equipment. Weaknesses There are disadvantages of the transient period.
Sample 1
Clinical Facilities. 7.1 The Facility agrees to provide:
Sample 1
Clinical Facilities. Section 1 (Clinical Facilities) of the Agreement is hereby amended to read in full as follows: The Hospital shall provide certain facilities (the “Hospital Facilities”) and staff (the “Hospital Personnel”), and the Foundation shall provide certain facilities (the “Foundation Facilities”) and staff (the “Foundation Personnel”), as hereafter described to be utilized in connection with the Nursing Program using Hospital Facilities and Foundation Facilities, and Hospital Personnel and Foundation Personnel, for a select number of students (the “ValleyCare Students”). In this Agreement, the Hospital Facilities and the Foundation Facilities may be referred to collectively as the “ValleyCare Facilities,” and the Hospital Personnel and the Foundation Personnel may be referred to collectively as the “ValleyCare Personnel.” The portion of the Nursing Program using ValleyCare Facilities and ValleyCare Personnel shall be referred to as the “Xxxxxx College Nursing Program – ValleyCare Extension.”
Sample 1

Related to Clinical Facilities

  • PUBLIC FACILITIES Supplier’s employees may be required to perform work at government- owned facilities, including schools. Supplier’s employees and agents must conduct themselves in a professional manner while on the premises, and in accordance with Participating Entity policies and procedures, and all applicable laws.

  • Toilet Facilities The Employer provides the Contractor access to toilet facilities. Temporary chemical toilets are provided by the Contractor where deemed necessary.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • TEACHER FACILITIES A. Each school shall have the following facilities:

  • Working Facilities During the Term of Employment, the Company shall furnish the Executive with an office, secretarial help and such other facilities and services suitable to his position and adequate for the performance of his duties hereunder.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • New Facilities For all new Generating Facilities to be interconnected pursuant to the Tariff, other than wind- powered and other non-synchronous generation facilities, the Generation Interconnection Customer shall design its Customer Facility to maintain a composite power delivery at continuous rated power output at a power factor of at least 0.95 leading to 0.90 lagging. For all new wind- powered and other non-synchronous generation facilities the Generation Interconnection Customer shall design its Customer Facility with the ability to maintain a composite power delivery at a power factor of at least 0.95 leading to 0.95 lagging across the full range of continuous rated power output. For all wind-powered and other non-synchronous generation facilities entering the New Service Queue on or after November 1, 2016, the power factor requirement shall be measured at the high-side of the facility substation transformers. This power factor range standard shall be dynamic and can be met using, for example, power electronics designed to supply this level of reactive capability (taking into account any limitations due to voltage level, real power output, etc.) or fixed and switched capacitors, or a combination of the two. For all wind-powered and other non-synchronous generation facilities entering the New Service Queue on or after May 1, 2015, and before November 1, 2016, the power factor requirement shall be measured at the generator’s terminals. For new generation resources of more than 20 MW, other than wind- powered and other non-synchronous Generating Facilities, the power factor requirement shall be measured at the generator’s terminals. For new generation resources of 20 MW or less, and all wind-powered and other non-synchronous generation facilities entering the New Service Queue prior to May 1, 2015, the power factor requirement shall be measured at the Point of Interconnection. Any different reactive power design criteria that Transmission Provider determines to be appropriate for a wind-powered or other non-synchronous generation facility shall be stated in the Interconnection Service Agreement. A Transmission Interconnection Customer interconnecting Merchant D.C. Transmission Facilities and/ or Controllable A.C. Merchant Transmission Facilities shall design its Customer Facility to maintain a power factor at the Point of Interconnection of at least 0.95 leading and 0.95 lagging, when the Customer Facility is operating at any level within its approved operating range.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Verizon OSS Facilities Any gateways, interfaces, databases, facilities, equipment, software, or systems, used by Verizon to provide Verizon OSS Services to CBB.

Time is Money Join Law Insider Premium to draft better contracts faster.